<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Douros Lab</title>
  <meta name="description" content="Douros Lab at Charité: Researching medication effects in vulnerable populations. 
	      Our studies assess drug effectiveness and safety in patients with liver disease, older adults, and those at 
	      risk of drug-drug interactions using large electronic healthcare databases.">
	
  <link rel="stylesheet" href="css/bootstrap.min.css">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.1/font/bootstrap-icons.css">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jpswalsh/academicons@1/css/academicons.min.css">
  <link rel="stylesheet" href="css/styles.css">
</head>

<body>
	
  <!-- Navigation Bar -->
  <nav class="navbar navbar-expand-lg navbar-light bg-light">
	<div class="container">
		<a class="navbar-brand" href="index.html">Douros Lab</a>
		<button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#collapsibleNavbar">
			<span class="navbar-toggler-icon"></span>
		</button>
		<div class="collapse navbar-collapse" id="collapsibleNavbar">
			<ul class="navbar-nav nav-underline me-auto">
				<li class="nav-item">
					<a class="nav-link remove-padding" href="index.html#talks">Talks</a>
				</li>
				<li class="nav-item">
					<a class="nav-link  remove-padding" href="index.html#publications">Publications</a>
				</li>
				<li class="nav-item">
					<a class="nav-link remove-padding" href="index.html#awards"><nobr>Grants and Awards</nobr></a>
				</li>
				<li class="nav-item">
					<a class="nav-link remove-padding" href="/html/research.html">Research</a>
				</li>
				<li class="nav-item">
					<a class="nav-link remove-padding" href="/html/team.html">Team</a>
				</li>
				<li class="nav-item">
					<a class="nav-link remove-padding" href="/html/team.html#collaborations">Collaborations</a>
				</li>
				<li class="nav-item">
					<a class="nav-link remove-padding" href="index.html#contact">Contact</a>
				</li>
			</ul>
			<ul class="navbar-nav"><!-- align to right and hide on md screens and smaller -->
				<li class="nav-item d-none d-lg-block">
					<a class="nav-link" href="https://www.charite.de/" target="_blank" rel="noopener">
						<img src="/img/charite.png" height="25" alt="Charité Berlin">
					</a>
				</li>
				<li class="nav-item d-none d-lg-block">
					<a class="nav-link" href="https://www.dfg.de/" target="_blank" rel="noopener">
						<img src="/img/dfg.png" height="25" alt="DFG">
					</a>
				</li>
			</ul>
		</div>
	</div>
  </nav>

 

  <section>	 
	<div class="container">
	   <div class="row py-5">
	   <!-- left column --> 
		 <div class="col-lg-4 text-center px-3">
			<img class="rounded-circle welcome-img" src="/img/ad.jpg" alt="Profile Image">
			<p></p>
			<h4>Prof. Dr. med.<br>Antonios Douros</h4>
			<h6><a href="mailto:antonios.douros@charite.de">antonios.douros@charite.de</a></h6>
			<p>
			  <h6>
			    <strong>Associate Professor of Pharmacoepidemiology</strong><br>
			    Institute of Clinical Pharmacology and Toxicology<br>
			    <nobr>Charité – Universitätsmedizin Berlin</nobr>
			  </h6>
		    </p>
			<br>
			<!-- mailto: -->
			 <a href="mailto:antonios.douros@charite.de">
			 <i class="bi bi-envelope" style="font-size: 1.7rem"></i></a>&nbsp; 

			<!-- Google Scholar: -->
			 <a href="https://scholar.google.com/citations?user=7ouKrX0AAAAJ&hl=en" target="_blank" rel="noopener">
			 <i class="ai ai-google-scholar-square ai-3x" style="font-size: 1.7rem"></i></a>&nbsp;

			<!-- ResearchGate: -->
			 <a href="https://www.researchgate.net/profile/Antonios-Douros" target="_blank" rel="noopener">
			 <i class="ai ai-researchgate ai-3x" style="font-size: 1.7rem"></i></a>&nbsp; 
			 
			<!-- Linkedin: -->
			 <a href="https://www.linkedin.com/in/antonios-douros-0a31a2173/" target="_blank" rel="noopener">
			 <i class="bi bi-linkedin"  style="font-size: 1.7rem"></i></a>&nbsp; 
					 
			<!-- Twitter-X: -->
			 <a href="https://twitter.com/AntoniosDouros/" target="_blank" rel="noopener">
			 <i class="bi bi-twitter-x" style="font-size: 1.7rem"></i></a>&nbsp; 	 

			<div class="d-md-block d-lg-none pt-2"><!-- hide div item on lg+ screens -->
			   <a href="https://www.charite.de/" target="_blank" rel="noopener"><img src="/img/charite.png" height="25" alt="Charité Berlin"></a>&nbsp; &nbsp; 
			   <a href="https://www.dfg.de/" target="_blank" rel="noopener"><img src="/img/dfg.png" height="25" alt="DFG"></a>
			</div>
		 </div> <!-- end left column -->
		 
		<!-- right column -->
		 <div class="col-lg-8">
		 
		 <!-- only md screen and up -->
		 <p>
		   <h2 class="d-none d-lg-block">Welcome</h2>
		 </p>
		 
		 <!-- only sm screen and lower -->
		 <p class="d-lg-none p-2">&nbsp;</p>
		 
		 <p>
		  I am an Associate Professor at the Institute of Clinical Pharmacology and Toxicology at Charité in Berlin and Head of the newly-established  
		  Douros Lab. The research in our lab focuses on the effectiveness and safety of medications in vulnerable populations, 
		  including patients with chronic liver disease, older adults, as well as patients subjected to polypharmacy and at risk of drug-drug interactions. 
		  Given the underrepresentation of such populations in randomized controlled trials, our lab aims to provide much needed evidence on the benefit-risk profile of drugs.
		<br><br>
		  For the implementation of our research program, we conduct both hypothesis-generating and hypothesis-testing studies. To this end, we use multiple data 
		  sources including spontaneous reports from the FDA Adverse Event Reporting System, German and Canadian administrative healthcare data, and electronic 
		  medical records from the United Kingdom. We also collaborate with several experts in the area of real world evidence in Canada, Germany, and Greece. The research in our 
		  lab is supported by the German Research Foundation and the Canadian Institutes of Health Research.  
		 </p>

		 <!-- inner row -->
		 <div class="row">
		   <!-- inner left column -->
		   <div class="col-md-4 p-3">
		   <h4>Interests</h4>
			 <ul>
			 <li>Pharmacoepidemiology</li>
			 <li>Pharmacovigilance</li>
			 <li>Clinical Pharmacology</li>
			 <li>Drug-drug interactions</li>
			 <li>Vulnerable populations</li>
			 </ul>

		   </div> 
		   <!-- end inner left column -->
		   
		   <!-- inner right column -->
		   <div class="col-md-8 p-3">	 
			 <h4>Education</h4>
			 <ul>
			 <li>Postdoc in Pharmacoepidemiology, McGill University</li>
			 <li>Doctorate Degree (Dr. med.), Charité – Universitätsmedizin Berlin</li>
			 <li>Medical Degree, Charité – Universitätsmedizin Berlin</li>
			 </ul>
		   </div>
		   <!-- end inner right column -->
		 </div> <!-- end inner row -->

   </div> <!-- end main column -->
  </div> <!-- end main row -->
</div> <!-- end container -->


<section id="experience"> 
<div class="container-fluid shadow-none py-5 px-0 bg-light">
  <div class="container">
	<div class="row">
	  <div class="col-lg-4"><h2 class="mt-5 mb-4 me-5">Experience</h2></div>
	  <div class="col-lg-8">
		  <ul class="list-unstyled">
		     <li class="mb-3">
				 <strong>2023 – present&nbsp;&nbsp;Associate Professor (Heisenberg)</strong><br>
				 Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin<br>
			 </li>
			 <li class="mb-3">
				 <strong>2023 – present&nbsp;&nbsp;Adjunct Professor</strong><br>
				 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University<br>
			 </li>
			 <li class="mb-3">
				 <strong>2023 – present&nbsp;&nbsp;Adjunct Professor</strong><br>
				 School of Epidemiology and Public Health, University of Ottawa<br>
			 </li>
			 <li class="mb-3">
				 <strong>2019 – 2023&nbsp;&nbsp;Assistant Professor</strong><br>
				 Department of Medicine (Division Clinical Epidemiology), McGill University<br>
			 </li>
			 <li class="mb-3">
				 <strong>2019 – 2023&nbsp;&nbsp;Investigator</strong><br>
				 Centre for Clinical Epidemiology (Pharmacoepidemiology Research Unit), Lady Davis Institute for Medical Research<br>
			 </li>
			 <li class="mb-3">
				 <strong>2019 – 2023&nbsp;&nbsp;Associate Member</strong><br>
				 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University<br>
			 </li>
			 <li class="mb-3">
				 <strong>2016 – 2018&nbsp;&nbsp;Postdoctoral Research Fellow</strong><br>
				 Centre for Clinical Epidemiology (Pharmacoepidemiology Research Unit), Lady Davis Institute for Medical Research<br>
			 </li>
			 <li class="mb-3">
				 <strong>2014 – 2015&nbsp;&nbsp;Research Fellow</strong><br>
				 Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS<br>
			 </li>
			 <li class="mb-3">
				 <strong>2012 – 2016&nbsp;&nbsp;Clinical Pharmacology Resident</strong><br>
				 Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin<br>
			 </li>
			 <li class="">
				 <strong>2009 – 2011&nbsp;&nbsp;Neurology Resident</strong><br>
				 Department of Early Neurological Rehabilitation & Intensive Care Unit, Medical Park Berlin Humboldtmühle<br>
		     </li>
		 </ul>
       </div>
    </div><!-- row end -->
  </div><!-- container end -->
</div><!-- container fluid end -->
</section>

<section id="talks"> 
<div class="container-fluid shadow-none py-5 px-0">
  <div class="container">
	<div class="row">
	  <div class="col-lg-4"><h2 class="mt-5 mb-4 me-5">Recent and Upcoming Talks</h2></div>
	  <div class="col-lg-8">
		 <ul class="list-unstyled">
		   <li class="mb-4">
			 <strong>Jun 1, 2024</strong>
			 <span class="fst-italic"> Repurposing antihypertensive drugs for MAFLD/NAFLD</span><br>
             33. European Meeting on Hypertension and Cardiovascular Protection<br>
			 European Society of Hypertension, Berlin, DE
		   </li>
		   <li class="mb-4">
			 <strong>Apr 15, 2024</strong>
			 <span class="fst-italic"> Break on through to the other side: from pharmacology to RWE</span><br>
             Mid-Year Meeting, International Society for Pharmacoepidemiology<br>
			 Orlando, FL
		   </li>
		   <li class="mb-4">
			 <strong>Mar 15, 2024</strong>
			 <span class="fst-italic"> Time-varying exposure definition in studying drug-drug interactions</span><br>
             Drug-Drug Interactions Special Interest Group Webinar<br>
			 International Society for Pharmacoepidemiology
		   </li>		   
		   <li class="">
			 <strong>Sep 12, 2023</strong> 
			 <span class="fst-italic"> Assessing the clinical effects of drug-drug interactions using cohort designs</span><br>
			 Therapeutics Research and Infectious Disease Epidemiology, Department of Population Medicine,<br> 
			 Harvard Medical School, Boston, MA
		   </li>
		 </ul>
       </div>
    </div><!-- row end -->
  </div><!-- container end -->
</div><!-- container fluid end -->
</section>


 <section id="publications">
    <div class="container-fluid shadow-none py-5 bg-light">
		<div class="container">
		  <div class="row">
			<h2>Publications</h2>
			<article>
				<p class="pt-4 pb-3">
				Please check out my complete list of publications on
				<a href="https://pubmed.ncbi.nlm.nih.gov/?term=(douros%20a%5BAuthor%5D)%20NOT%20response%20%5BTitle%5D%20NOT%20flavonoids%20%5BTitle%5D%20NOT%20infants%20%5BTitle%5D%20NOT%20erratum%5BTitle%5D%20NOT%20Re%3A%5BTitle%5D%20NOT%2036027118&sort=pubdate" target="_blank" rel="noopener">PubMed</a>.
				</p>
				<p>				
				To date, my research has resulted in 78 peer-reviewed publications (36 as first author, 14 as senior author).
				Several of these publications have appeared in top-tier journals including the
				<i>British Medical Journal</i> (4x), <i>Annals of Internal Medicine</i>, <i>European Heart Journal</i>,
				<i>Journal of the American College of Cardiology</i>, <i>Diabetes Care</i> (7x),
				<i>Alzheimer’s & Dementia</i>, <i>JACC: Heart Failure</i>,
				and <i>Neurology</i>. Moreover, my publications have been the subject of 10 editorials. Below are a few highlights of my published work.
				</p>
			</article>
		  </div>
		  
		  <div class="row py-5">
			<!-- Modal -->
			  <div class="modal fade" id="imageModal" tabindex="-1" aria-labelledby="imageModalLabel" aria-hidden="true">
				  <div class="modal-dialog modal-xl">
					  <div class="modal-content">
						  <div class="modal-header">
							  <button type="button" class="btn-close" data-bs-dismiss="modal" aria-label="Close"></button>
						  </div>
						  <div class="modal-body text-center">
							  <img class="img-fluid" id="enlargedImage" src="" alt="Enlarged Image">
						  </div>
					  </div>
				  </div>
			  </div>  
			  
            <div class="col-lg-4 p-3">
			  <div class="d-none d-lg-block"><!-- show modal only on large screen -->
			    <figure class="figure">
                            <img class="img-fluid float-start clickable-image" src="/img/forestplot.jpg" alt="Forest plot NOAC and Liver Injury" data-bs-toggle="modal" data-bs-target="#imageModal" data-src="/img/forestplot.jpg">
			       <figcaption class="figure-caption text-end"><i class="bi bi-zoom-in" style="font-size: 1rem"></i></figcaption>
                             </figure>			  
			  </div>
			  <div class="d-lg-none"><!-- show simple image on small screen -->
			    <img class="img-fluid float-start" src="/img/forestplot.jpg" alt="Forest plot NOAC and Liver Injury">
			  </div>
			</div>
			  
			<div class="col-lg-8 p-3">
			  <article>
				<h3>Real-world effects of direct oral anticoagulants</h3>
				<p>
				Direct oral anticoagulants (DOACs) are blood thinners that are used to prevent and treat thrombotic disease. 
				The most common indications include non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). 
				During my work at McGill University, I studied the utilization of DOACs in various populations including patients with NVAF
				<a href="https://pubmed.ncbi.nlm.nih.gov/28984052" target="_blank" rel="noopener">here</a> and patients with NVAF and underlying liver disease
				<a href="https://pubmed.ncbi.nlm.nih.gov/34409636/" target="_blank" rel="noopener">here</a>. I also addressed important safety concerns related to the use of DOACs. 
				For example, I assessed their risk of liver injury
				<a href="https://pubmed.ncbi.nlm.nih.gov/29519351/" target="_blank" rel="noopener">here</a> (see also Graphical Abstract), 
				thereby showing that DOACs do not increase the risk of this potentially fatal adverse effect when compared to the therapeutic alternative vitamin K antagonists. These findings provided reassurance regarding the hepatic safety of DOACs. 
				I also studied their risk of esophageal disorders
				<a href="https://pubmed.ncbi.nlm.nih.gov/32377758/" target="_blank" rel="noopener">here</a>, and their risk of major bleeding when used together with antiplatelet agents in patients with NVAF
				<a href="https://pubmed.ncbi.nlm.nih.gov/30691551/" target="_blank" rel="noopener">here</a> and in patients with VTE
				<a href="https://pubmed.ncbi.nlm.nih.gov/35036824" target="_blank" rel="noopener">here</a>.
				Moreover, I assessed the effectiveness and safety of DOACs in high-risk populations such as 
				patients with NVAF and underlying liver disease <a href="https://pubmed.ncbi.nlm.nih.gov/38552497/" target="_blank" rel="noopener">here</a>,	
				octogenarians with VTE
				<a href="https://pubmed.ncbi.nlm.nih.gov/36150513/" target="_blank" rel="noopener">here</a> and patients with cancer related thrombosis
				<a href="https://pubmed.ncbi.nlm.nih.gov/33836492/" target="_blank" rel="noopener">here</a>.
			   </p>
			 </article>
			</div>
		  </div>

		  <div class="row pb-5">
			<div class="col-lg-4 p-3">
			   <div class="d-none d-lg-block"><!-- show modal only on large screen -->
			     <figure class="figure">
			       <img class="img-fluid float-start clickable-image" src="/img/sulfonylureas.png" alt="Infographic Sulfonylureas" data-bs-toggle="modal" data-bs-target="#imageModal" data-src="/img/sulfonylureas.png">
			       <figcaption class="figure-caption text-end"><i class="bi bi-zoom-in" style="font-size: 1rem"></i></figcaption>
                             </figure>
			   </div>
			   <div class="d-lg-none"><!-- show simple image on small screen -->
			     <img class="img-fluid float-start" src="/img/sulfonylureas.png" alt="Infographic Sulfonylureas">
			   </div>
			</div>			
			<div class="col-lg-8 p-3">
			  <article>
				<h3>Safety of sulfonylureas</h3>
				<p>
				Sulfonylureas are oral antidiabetic drugs commonly used in the management of type 2 diabetes. 
				They are efficacious in controlling blood glucose levels; however, there are concerns regarding their cardiovascular and hypoglycemic safety. 
				During my work at McGill, I studied the safety of sulfonylureas, both as first-line treatments
				<a href="https://pubmed.ncbi.nlm.nih.gov/28864502/" target="_blank" rel="noopener">here</a> and second-line treatments
				<a href="https://pubmed.ncbi.nlm.nih.gov/30021781/" target="_blank" rel="noopener">here</a>.
				I also specifically studied the safety of glimepiride, a sulfonylurea often used as active comparator in randomized controlled trials assessing the effects of newer antidiabetic drugs
				<a href="https://pubmed.ncbi.nlm.nih.gov/31596043/" target="_blank" rel="noopener">here</a>.
				Recently, several studies funded by the Canadian Institutes of Health Research and led by my trainee Jenny Dimakos focused on the risk of severe hypoglycemia due to concomitant use of 
				sulfonylureas and warfarin
				<a href="https://pubmed.ncbi.nlm.nih.gov/35984011" target="_blank" rel="noopener">here</a>, beta-blockers
				<a href="https://pubmed.ncbi.nlm.nih.gov/36525638" target="_blank" rel="noopener">here</a> (see also Graphical Abstract) and dipeptidyl peptidase-4 inhibitors
				<a href="https://pubmed.ncbi.nlm.nih.gov/37326010" target="_blank" rel="noopener">here</a>.
				Overall, this work has advanced our understanding regarding the overall safety of profile of these commonly used antidiabetic drugs.
				</p>
			  </article>
			</div>
		  </div>

		  <div class="row pb-5">
			<div class="col-lg-4 p-3">
			  <div class="d-none d-lg-block"><!-- show modal only on large screen -->
			    <figure class="figure">
			      <img class="img-fluid float-start border clickable-image" src="/img/sodiumglucose.jpg" alt="Infographic Sodium-glucose co-transporter 2 inhibitors" data-bs-toggle="modal" data-bs-target="#imageModal" data-src="/img/sodiumglucose.jpg">
			      <figcaption class="figure-caption text-end"><i class="bi bi-zoom-in" style="font-size: 1rem"></i></figcaption>
                            </figure>
			  </div>
			  <div class="d-lg-none"><!-- show simple image on small screen -->
			     <img class="img-fluid float-start" src="/img/sodiumglucose.jpg" alt="Infographic Sodium-glucose co-transporter 2 inhibitors">
			   </div>
			</div>
			<div class="col-lg-8 p-3">
			  <article>
			  <h3>Safety of sodium-glucose co-transporter 2 inhibitors</h3>
			  <p>
				Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer class of oral antidiabetic drugs used in the management of type 2 diabetes and other cardiometabolic conditions. 
				In 2020, I was selected to lead an international, multicenter study on their safety. The study was conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), 
				one of the largest pharmacoepidemiologic networks in the world. The aim was to assess the risk of diabetic ketoacidosis with SGLT2 inhibitors, 
				which was an important safety concern according to several regulatory agencies. We observed an almost 3-fold increased risk of this potentially fatal adverse effect with SGLT2 inhibitors
				<a href="https://pubmed.ncbi.nlm.nih.gov/32716707/" target="_blank" rel="noopener">here</a> (see also Graphical Abstract). 
				Outside of CNODES, I have also studied their risk of VTE as part of our collaboration with the InGef – Institut für angewandte Gesundheitsforschung Berlin
				<a href="https://pubmed.ncbi.nlm.nih.gov/33316246" target="_blank" rel="noopener">here</a> 
				and the safety of their interaction with statins as part of our collaboration with the School of Epidemiology and Public Health at the University of Ottawa
				<a href="https://pubmed.ncbi.nlm.nih.gov/36912450/" target="_blank" rel="noopener">here</a>.
			  </p>
			  </article>
			</div>
		</div>
	  </div>
	</div>
  </section><!-- section publications end -->


 
<section id="awards"> 
    <div class="container-fluid shadow-none py-5 px-0">
	  <div class="container">
	    <div class="row">
		  <div class="col-lg-4"></div>
          <div class="col-lg-8"><h2 class="mt-5 mb-4 me-5 text-start">Grants, Awards & Distinctions</h2></div>		  
		</div>
		<div class="row mb-3">
          <div class="col-lg-4"> 
            <h2 class="mt-5 mb-2 me-5">Research Grants as PI</h2>
          </div>
          <div class="col-lg-8">
			<div class="card">
					<div class="card-body pb-0">
						<ul class="list-unstyled">
							<li class="mb-4">
								<strong>2019-2023 Project Grant <span class="text-muted">(CAD 225,676.00)</span>
								<div class="d-md-none"></div> Canadian Institutes of Health Research</strong><br>
								<span class="fst-italic">
								Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease
								</span>
							</li>
							<li class="mb-4">
								<strong>2019-2022 Project Grant <span class="text-muted">(CAD 149,176.00)</span>
								<div class="d-md-none"></div> Canadian Institutes of Health Research</strong><br>
								<span class="fst-italic">
								Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes
								</span>
							</li>
						</ul>
					</div>
			</div>
          </div>
        </div>	
		<div class="row my-3">
          <div class="col-lg-4"> 
            <h2 class="mt-5 mb-2 me-5">Personal Salary Awards</h2>
          </div>
         <div class="col-lg-8">	
			<div class="card">
					<div class="card-body pb-0">
						<ul class="list-unstyled">
						<li class="mb-4">
							<strong>2023-2028 Heisenberg Program <span class="text-muted">(EUR 630,000.00)</span>
							<div class="d-md-none"></div> German Research Foundation</strong><br>
							<span class="fst-italic">
							Effectiveness and safety of medications in vulnerable populations
							</span>
						</li>
						<li class="mb-4">
							<strong>2020-2023 Junior 1 Salary Support Award <span class="text-muted">(CAD 364,901.00)</span>
							<div class="d-md-none"></div> Fonds de recherche du Québec – Santé</strong><br>
							<span class="fst-italic">
							Efficacité et innocuité des médicaments dans les populations vulnérables
							</span>
						</li>
						<li class="mb-4">
							<strong>2016-2018 Research Fellowship <span class="text-muted">(EUR 122,626.00)</span>
							<div class="d-md-none"></div> German Research Foundation</strong><br>
							<span class="fst-italic">
							Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants in stroke prevention in atrial fibrillation
							</span>
						</li>
					</ul>
				</div>
			</div>
		</div>
		</div>			
		<div class="row my-3">
          <div class="col-lg-4"> 
            <h2 class="mt-5 mb-2 me-5">Other Personal Awards</h2>
          </div>
         <div class="col-lg-8">	
			<div class="card">
					<div class="card-body pb-0">					
					<ul class="list-unstyled">
					  <li class="mb-4"><strong>2022 Excellence in Teaching Epidemiology (2021-2022)</strong><br>Epidemiology, Biostatistics and Occupational Health Student Society, McGill Department of Epidemiology, Biostatistics and Occupational Health</li>
					  <li class="mb-4"><strong>2022 Travel Grant</strong><br>European Renal Association</li>
					  <li class="mb-4"><strong>2021 Comparative Effectiveness Research Special Interest Group Spotlight Poster Award</strong><br>International Society for Pharmacoepidemiology</li>
					  <li class="mb-4"><strong>2018 Second Best Abstract by a Student/ Postdoc</strong><br>International Society for Pharmacoepidemiology</li>
					</ul>
					</div>
			</div>
         </div>
        </div>		
	    <div class="row my-3">
          <div class="col-lg-4"> 
            <h2 class="mt-5 mb-2 me-5">Distinctions</h2>
          </div>
         <div class="col-lg-8">					
			<div class="card">
				<div class="card-body">
					<ul class="list-unstyled my-2">
					  <li><strong>2023 Appointment as Full Member</strong> 
					  <div class="d-md-none"></div> Canadian Institutes of Health Research College of Reviewers</li>
					  <li class="mb-4"><strong>2022 Appointment as Associate Member</strong> 
					  <div class="d-md-none"></div> Canadian Institutes of Health Research College of Reviewers</li>					  

					  <li><strong>2023 Paper of the Month</strong>
					  <div class="d-md-none"></div> Lady Davis Institute for Medical Research,  
					  <a href="https://pubmed.ncbi.nlm.nih.gov/37073411/" target="_blank" rel="noopener">Apr 2023</a></li>
					  <li><strong>2019 Paper of the Month</strong> 
					  <div class="d-md-none"></div> Lady Davis Institute for Medical Research,  
					  <a href="https://pubmed.ncbi.nlm.nih.gov/30805599/" target="_blank" rel="noopener">Jul 2019</a></li>
					  <li><strong>2019 Paper of the Quarter</strong> 
					  <div class="d-md-none"></div> Charité Institute of Biometry and Clinical Epidemiology, 
					  <a href="https://pubmed.ncbi.nlm.nih.gov/30805599/" target="_blank" rel="noopener">Apr 2019</a></li>
					  <li class="mb-4"><strong>2018 Paper of the Month</strong> 
					  <div class="d-md-none"></div> Lady Davis Institute for Medical Research, 
					  <a href="https://pubmed.ncbi.nlm.nih.gov/29519351/" target="_blank" rel="noopener">Jul 2018</a></li>					  
					  
					  <li><strong>2022 Best Reviewer</strong> 
					  Annals of Internal Medicine</li>
					  <li><strong>2019 Best Reviewer</strong> 
					  Annals of Internal Medicine</li>					  
					  <li><strong>2019 Best Reviewer</strong> 
					  Pharmacoepidemiology and Drug Safety</li>
					  <li><strong>2018 Best Reviewer</strong> 
					  Pharmacoepidemiology and Drug Safety</li>
					  <li class="mb-4"><strong>2015 Best Reviewer</strong> 
					  Pharmacoepidemiology and Drug Safety</li>
					</ul>
				</div>
			</div>
		</div>
	  </div>		 
</div>
</div>
</section><!-- section awards end -->


  <footer>
	<!-- CONTACT SECTION -->
	<section id="contact">
  <br><br><br>
	 <div class="impressum" lang="de">
	  <div class="container-fluid shadow-none py-5 mb-5 bg-light">
		<div class="container">
		  <div class="row">
		  <div class="col-lg-4 text-center text-lg-start">
			<p><h4>Contact &middot; Impressum</h4></p>
		  </div>
		  <div class="col-lg-4 text-center text-lg-start">
			<p><h5>Address:</h5>
			<p>
		    Prof. Dr. med. Antonios Douros<br>
			Institut für Klinische Pharmakologie und Toxikologie<br>
			Charité – Universitätsmedizin Berlin<br>
			Charitéplatz 1, 10117 Berlin, Germany
			</p>
		  </div>
		  <div class="col-lg-4 text-center text-lg-start">
			<p><h5>Email:</h5>
			<p><a href="mailto:antonios.douros@charite.de">antonios.douros@charite.de</a></p>
		  </div>
		</div>
	  </div>
    </div>
<!-- Copyright -->
    <div class="container-fluid">
		<div class="container">
		<div class="row">
		  <div class="col-lg-4"><!-- Empty cell --></div>
		  <div class="col-lg-8 text-center text-md-start"><p class="text-muted">&copy; 2023-2024 Antonios Douros. <a href="html/privacy.html">Datenschutzerklärung</a></p></div>
		</div>
	  </div>
	 </div> 
	</section>
	<!-- END CONTACT SECTION -->
  </footer>


  <!-- JavaScript -->
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-YvpcrYf0tY3lHB60NNkmXc5s9fDVZLESaAA55NDzOxhy9GkcIdslK1eN7N6jIeHz" crossorigin="anonymous"></script>
  <script src="js/scripts.js"></script>
</body></html>
